tbuckley/cabot-search huggingface dataset:
P1.14-08 Activity of Poziotinib and Other 2nd-Gen Quinazoline EGFR TKIs in Atypical Exon18 and Acquired Osimertinib Resistance Mutants
Authors: J. Robichaux, X. Le, Y. Elamin, M. Nilsson, L. Hu, J. He, F. Zhang, A. Poteete, H. Sun, W. Rinsurongkawong, J. Cross, J. Heymach
Journal: Journal of Thoracic Oncology (2019)
Druggable Genome siRNA-Screening Identifies Glybenclamide as a Radioprotector against Total Body Irradiation
Authors: Peter R McDonald, Jian Fei Jiang, Tracy Dixon, Darcy Franicola, Xichen Zhang, Suhua Nie, Laura Epperly, Valerian Kagan, John Lazo, Michael W Epperly, Joel S Greenberger
Journal: Blood (2008)
Non-Myeloablative Conditioning with Busulfan Prior to Allogeneic Hematopoietic Stem Cell Transplant Results in Mixed Chimerism and Reversal of the Phenotype in Canine Leukocyte Adhesion Deficiency with Minimal Regimen Related Toxicity and without Graft-vs.-Host Disease.
Authors: Robert A. Sokolic, Yu-Chen Gu, Tanya Burkholder, Laura M. Tuschong, Mehreen Hai, Thomas R. Bauer, Dennis D. Hickstein
Journal: Blood (2004)
Sports-related concussion (SRC) in road cycling: the RoadsIde heaD Injury assEssment (RIDE) for elite road cycling
Authors: Neil Heron, Jonathan Elliott, Nigel Jones, Mike Loosemore, Simon Kemp
Journal: British Journal of Sports Medicine (2019)

Sports-related concussion (SRC) is a recognised sport-related injury and a growing global public health concern,1 accounting for between 1.3% and 9.1% of all injuries reported during cycling events.2 Road cycling, however, does not have a sport-specific SRC assessment protocol,3 particularly lacking a roadside screening (‘go/no go’) assessment protocol. We would therefore like to propose the creation of a cycling specific RoadsIde heaD injury assEssment (RIDE) protocol

In order to account for the often transient, evolving or delayed onset of SRC symptoms, serial clinical evaluations should be embedded within a three-stage process to optimise the diagnosis of SRC.4 This RIDE protocol will evolve as epidemiological evidence on SRC in road cycling develops4 5 and feedback is received from interested parties.

The three-stage diagnostic process involves (see figure 1):



Figure 1 
Cycling RoadsIde heaD Injury assEssment (RIDE) protocol (adapted from World Rugby HIA protocol).7 



1. Initial road-side assessment immediately following head impact event (RIDE 1).

2. Reassessment immediately following completion of the stage on the same day of the injury (RIDE 2).

3. Reassessment the day following the initial injury …
Impact of EGFR mutation and ALK rearrangement on the outcomes of non–small cell lung cancer patients with brain metastasis
Authors: Suresh K Balasubramanian, Mayur Sharma, Vyshak A Venur, Philipp Schmitt, Rupesh Kotecha, Samuel T Chao, John H Suh, Lilyana Angelov, Alireza M Mohammadi, Michael A Vogelbaum, Gene H Barnett, Xuefei Jia, Nathan A Pennell, Manmeet S Ahluwalia
Journal: Neuro-Oncology (2019)

Abstract Background The impact of activating alterations in non–small cell lung cancer (NSCLC) (epidermal growth factor receptor [EGFR] mutation/anaplastic lymphoma kinase [ALK] translocation) in prognosticating patients with brain metastasis (BM) is not well defined. This study was sought to identify this impact in NSCLC patients with BM accounting for the known validated variables. Methods Among 1078 NSCLC-BM patients diagnosed/treated between January 1, 2000 and December 31, 2015, three hundred and forty-eight with known EGFR/ALK status were analyzed. Overall survival (OS) and intracranial progression-free survival (PFS) were measured from the time of BM. Results Ninety-one patients had either ALK (n = 23) alterations or EGFR (n = 68) mutation and 257 were wild type (WT; negative actionable mutations/alterations). Median age of EGFR/ALK+ NSCLC BM patients was 60 years (range 29.8–82.6 y) and ~50% (n = 44) had Karnofsky performance status (KPS) score &gt;80. Median number of BM was 2 (1 to ≥99). The median OS for the ALK/EGFR+ NSCLC BM was 19.9 versus 10.1 months for the WT (P = 0.028). The number of BM in the EGFR/ALK+ group did not impact OS (BM = 1 with 21.1 months vs 2–3 with 19.1 months and &gt;3 with 23.7 months, P = 0.74), whereas fewer BM in the WT cohort had significantly better OS (BM = 1 with 13.8 mo, 2–3 with 11.0 mo and &gt;3 with 8.1 mo; P = 0.006) with the adjustment of age, KPS, symptoms from BM and synchronicity. Conclusions Number of BM does not impact outcomes in the EGFR/ALK+ NSCLC patients, implying that targeted therapy along with surgery and/or radiation may improve OS irrespective of the number of BM. Number of BM, extracranial metastasis (ECM), and KPS independently affected OS/PFS in WT NSCLC BM, which was consistent with the known literature.
P1.01-115 Long-Term Effects of Concurrent Chemoradiotherapy on Quality of Life in Locally Advanced Non-Small Cell Lung Cancer Patients
Authors: I. Walraven, E. Veldhuijzen, J. Aerts, F. Koppe, E. Dieleman, P. Van De Vaart, M. Van Den Heuvel, J. Belderbos
Journal: Journal of Thoracic Oncology (2019)
P1.13-12 The Invasion of Mediastinal Fat Tissue Should be Considered for T4 Description in the Next TNM Classification of NSCLC
Authors: N. Citak, Y. Aksoy, O. Isgörücü, C. Obuz, B. Acikmese, S. Büyükkale, N. Fener, M. Metin, A. Sayar
Journal: Journal of Thoracic Oncology (2019)
P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases
Authors: S. Ekman, A. Varrone, A. Jucaite, K. Vishwanathan, A. Brown, Z. Cselényi, H. Martin, R. Lewensohn, M. Schou, G. Laus, J. Van Der Aart, P. Johnström, N. Singh, L. Farde
Journal: Journal of Thoracic Oncology (2019)
EP1.12-32 Clinico-Pathological Features of Small Cell Lung Cancer in Albanian Patients
Authors: D. Xhemalaj, P. Kapisyzi, S. Bala, H. Hafizi, F. Gradica, E. Hila, J. Tula, A. Andoni, M. Krushova
Journal: Journal of Thoracic Oncology (2019)
EP1.16-18 EGFR Mutation Positive Non-Small Cell Lung Cancer: Management Approach and Survival Outcomes from the Hospital of Leon
Authors: I. Delgado Sillero, M. López Flores, L.F. Sánchez-Cousido, M. Rojas Piedra, N. Lopetegui Lia, N. Alonso, C. Diez Tascon, A. López González, C. Castañón, L. De Sande, Á. Rodriguez, M. Pedraza, B. Nieto Mangudo, A. García-Palomo, P. Diz
Journal: Journal of Thoracic Oncology (2019)
Ehlers-Danlos syndromes: new labels confuse everyone
Authors: Anthony N Williams
Journal: BMJ (2019)

Over the past 15 years, my caseload of patients with Ehlers-Danlos syndromes (EDS)4 has increased from two a year to two a month. Almost all have hypermobile EDS. The 2017 classification aimed to tighten the categorisation of EDS1 but seems to have substantially increased the number of patients instead. The new diagnostic approach is of the “pick and mix” variety; careful selection shows that all …
P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)
Authors: R. Garcia Campelo, H. Lin, M. Perol, M. Jahanzeb, S. Popat, Y. Zhu, P. Zhang, D.R. Camidge
Journal: Journal of Thoracic Oncology (2019)
PL02.06 In Hospital Clinical Efficacy, Safety and Oncologic Outcomes from VIOLET: A UK Multi-Centre RCT of VATS Versus Open Lobectomy for Lung Cancer
Authors: E. Lim, T. Batchelor, J. Dunning, M. Shackcloth, V. Anikin, B. Naidu, E. Belcher, M. Loubani, V. Zamvar, T. Brush, L. Dabner, R. Harris, D. Phillips, C. Beard, H. Mckeon, S. Paramasivan, D. Elliott, A. Realpe Rojas, E. Stokes, S. Wordsworth, J. Blazeby, C. Rogers, T. Violet Trialists
Journal: Journal of Thoracic Oncology (2019)
P2.04-25 Gut Mycobiome and Metabolic Interactions with Bacteria in Lung Cancer Patients Reveals Potential Therapeutic Vulnerabilities
Authors: Z. Lohinai, R. Santhanam, J. Heshiki, N. Dora, E. Dulka, G. Ostoros, B. Döme, S. Morten, G. Panagiotou, G. Weiss
Journal: Journal of Thoracic Oncology (2019)
MA20.01 Global Quantitative Mass Spectrometry Reveals Potential Novel Actionable Targets in Thymic Epithelial Tumors (TET)
Authors: X. Zhang, Y. Qi, F. Kirkali, T. Huang, T. Maity, K. Nguyen, D. Schrump, O. Vitek, A. Rajan, U. Guha
Journal: Journal of Thoracic Oncology (2019)
The Abnormal Presence of Mitochondria in Circulating Red Blood Cells Cause an Increased Oxygen Consumption Rate, ROS Generation and Hemolysis in Patients with Sickle Cell Disease
Authors: Ramasamy Jagadeeswaran, Hong Lenny, Benjamin Vazquez, Joshua Muniz, Aimee Schad, Shivi Jain, Michel Gowhari, Donald Lavelle, Alan Diamond, Robert E. Molokie, Angela Rivers
Journal: Blood (2017)
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
Authors: J. Diels, P. Thilakarathne, C. Cameron, S. McElligott, A. Schubert, L. Puig
Journal: British Journal of Dermatology (2019)

Guselkumab is an interleukin-23 inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long-term efficacy comparisons of guselkumab and ustekinumab are currently lacking among ustekinumab-naive patients.
Iron Binding to Specific Lobes of Transferrin Differentially Affects Erythropoiesis and Hepcidin Signaling
Authors: Nermi Parrow, Amaliris Gonzalez, Yihang Li, Princy Prasad, Luke Mammen, Faris Ali, Edvinas Vaicikauskas, Maria Feola, Yelena Ginzburg, Stefano Rivella, Robert E Fleming
Journal: Blood (2017)
Chronic Stress Induces Activity, Synaptic, and Transcriptional Remodeling of the Lateral Habenula Associated with Deficits in Motivated Behaviors
Authors: Ignas Cerniauskas, Jochen Winterer, Johannes W. de Jong, David Lukacsovich, Hongbin Yang, Fawwad Khan, James R. Peck, Sophie K. Obayashi, Varoth Lilascharoen, Byung Kook Lim, Csaba Földy, Stephan Lammel
Journal: Neuron (2019)
Loss of Imprinting in Human Placentas Is Widespread, Coordinated, and Predicts Birth Phenotypes
Authors: Claudius Vincenz, Jennie L Lovett, Weisheng Wu, Kerby Shedden, Beverly I Strassmann
Journal: Molecular Biology and Evolution (2019)

Genomic imprinting leads to mono-allelic expression of genes based on parent of origin. Therian mammals and angiosperms evolved this mechanism in nutritive tissues, the placenta, and endosperm, where maternal and paternal genomes are in conflict with respect to resource allocation. We used RNA-seq to analyze allelic bias in the expression of 91 known imprinted genes in term human placentas from a prospective cohort study in Mali. A large fraction of the imprinted exons (39%) deviated from mono-allelic expression. Loss of imprinting (LOI) occurred in genes with either maternal or paternal expression bias, albeit more frequently in the former. We characterized LOI using binomial generalized linear mixed models. Variation in LOI was predominantly at the gene as opposed to the exon level, consistent with a single promoter driving the expression of most exons in a gene. Some genes were less prone to LOI than others, particularly lncRNA genes were rarely expressed from the repressed allele. Further, some individuals had more LOI than others and, within a person, the expression bias of maternally and paternally imprinted genes was correlated. We hypothesize that trans-acting maternal effect genes mediate correlated LOI and provide the mother with an additional lever to control fetal growth by extending her influence to LOI of the paternally imprinted genes. Limited evidence exists to support associations between LOI and offspring phenotypes. We show that birth length and placental weight were associated with allelic bias, making this the first comprehensive report of an association between LOI and a birth phenotype.
P1.01-116 Early Immune-Related Adverse Events Under PD-1/PD-L1 Inhibitors Predict Better Progression-Free Survival in NSCLC
Authors: M. Boussageon, S. Ortiz-Cuaran, S. Chabaud, D. Pérol, V. Avrillon, B. Mastroianni, J. Fayette, F. Ghiringhelli, E. Neidhardt, A. Swalduz, V. Paulus, C. Kaderbhai, J. Fumet, P. Saintigny, M. Perol
Journal: Journal of Thoracic Oncology (2019)
P2.01-44 Promoter Polymorphisms of TOP2A and ERCC1 Genes as Predictive Factors for Chemotherapy in Non-Small Cell Lung Cancer Patients
Authors: A. Grenda, J. Błach, P. Krawczyk, M. Nicoś, M. Szczyrek, B. Kuźnar-Kamińska, M. Jakimiec, H. Batura-Gabryel, M. Sawicki, J. Milanowski
Journal: Journal of Thoracic Oncology (2019)
P2.12-20 NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab in LS-SCLC
Authors: K. Higgins, C. Hu, H. Ross, S. Jabbour, D. Kozono, T. Owonikoko, B. Movsas, C. Xiao, T. Solberg, T. Williams, J. Simko, X. Wang, T. Stinchcombe, J. Bradley
Journal: Journal of Thoracic Oncology (2019)
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial
Authors: Lise M Verhoef, Nathan den Broeder, Rogier M Thurlings, Willemijn H van der Laan, Wilfred van der Weele, Marc R Kok, Hein J Bernelot Moens, Thasia G Woodworth, Bart J F van den Bemt, Frank H J van den Hoogen, Alfons A den Broeder
Journal: The Lancet Rheumatology (2019)
EP1.08-04 Local Treatment for Patients with Pulmonary Oligo-Recurrence of Non-Small Cell Lung Cancer
Authors: Y. Kitamura, W. Nishio, S. Sekii, Y. Fujibayashi, M. Nishikubo, Y. Nishioka, H. Ogawa, S. Tane, K. Tsujino, M. Yoshimura
Journal: Journal of Thoracic Oncology (2019)
Successful closure of a colon perforation via the over-the-scope-clip system after accidental ingestion of a fish bone
Authors: Tsuyoshi Suda, Shingo Soga, Naoki Oishi, Takuya Seike, Koichi Hirose
Journal: Endoscopy (2019)

Bowel perforation due to accidental ingestion of foreign bodies is rare, and large-bowel perforation is rarer [1]. An 87-year-old man was admitted for removal of a foreign body in the colon, which was detected incidentally on computed tomography (CT) following penetration of the sigmoid colon ([Fig. 1]). The foreign body was not detected on radiography. As the patient had no symptoms or abdominal rigidity, we planned to remove the foreign body endoscopically ([Video 1]).
P2.14-24 An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC
Authors: X. Le, V. Zhu, A. Saltos, P. Nikolinakos, K. Mileham, V. Velcheti, H. Husain, M. Nilsson, H. Tran, E. Roarty, E. Kim, S. Ou, R. Sanborn, J.E. Gray, K. Wong, N. Hanna, V. Papadimitrakopoulou, J. Heymach
Journal: Journal of Thoracic Oncology (2019)
The Culture of Trial Results Reporting at Academic Medical Centers
Authors: Deborah A. Zarin
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
P1.01-68 Monitoring Clinical Responses Measuring PD-L1 in cfRNA in Plasma of Non-Small Cell Lung Cancer Patients Undergoing Systemic Therapy
Authors: L. Raez, J. Usher, K. Danenberg, D. Sumarriva, B. Hunis, G. Domingo, Y. Jaimes, P. Danenberg, S. Rabizadeh
Journal: Journal of Thoracic Oncology (2019)
MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients
Authors: E. Gobbini, A.C. Toffart, M. Perol, J. Assié, M. Duruisseaux, D. Coupez, R. Gervais, V. Westeel, M. Delaunay, F. Guisier, R. Veillon, V. Gounant, E. Giroux Leprieur, F.R. Vanel, N. Chaabane, E. Dansin, H. Babey, C. Decroisette, F. Barlesi, N. Girard, P. Fournel, L. Mezquita, Y. Oulkhouir, A. Canellas, B. Duchemann, O. Molinier, D. Moro-Sibilot, M. Giaj Levra
Journal: Journal of Thoracic Oncology (2019)
MA06.03 Poor Pulmonary Function Does Not Define “Medical Inoperability”: Short and Long Term Results of a Matched Lung Cancer Cohort
Authors: A. Sholi, M. Kamel, A. Nasar, A. Naik, S. Harrison, B. Lee, J. Port, N. Altorki, B. Stiles
Journal: Journal of Thoracic Oncology (2019)
P1.14-30 Phase I Study of Afatinib Plus Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
Authors: T. Tokito, R. Ko, C. Imamura, T. Shukuya, N. Shimada, R. Koyama, K. Yamada, H. Ishii, K. Azuma, K. Takahashi
Journal: Journal of Thoracic Oncology (2019)
Asymmetric Distribution of Gene Trees Can Arise under Purifying Selection If Differences in Population Size Exist
Authors: Chong He, Dan Liang, Peng Zhang
Journal: Molecular Biology and Evolution (2019)

Incomplete lineage sorting (ILS) is an important factor that causes gene tree discordance. For gene trees of three species, under neutrality, random mating, and the absence of interspecific gene flow, ILS creates a symmetric distribution of gene trees: the gene tree that accords with the species tree has the highest frequency, and the two discordant trees are equally frequent. If the neutral condition is violated, the impact of ILS may change, altering the gene tree distribution. Here, we show that under purifying selection, even assuming that the fitness effect of mutations is constant throughout the species tree, if differences in population size exist among species, asymmetric distributions of gene trees will arise, which is different from the expectation under neutrality. In extremes, one of the discordant trees rather than the concordant tree becomes the most frequent gene tree. In addition, we found that in a real case, the position of Scandentia relative to Primate and Glires, the symmetry in the gene tree distribution can be influenced by the strength of purifying selection. In current phylogenetic inference, the impact of purifying selection on the gene tree distribution is rarely considered by researchers. This study highlights the necessity of considering this impact.
MA23.02 CDK4/6 Inhibitors Show Antitumor Effects in Preclinical Models of Malignant Pleural Mesothelioma
Authors: E. Aliagas, M. Martínez-Iniesta, M. Hernández, A. Alay, D. Cordero, X. Solé, F. Rivas, A. Ureña, N. Vilariño, C. Muñoz-Pinedo, A. Villanueva, E. Nadal
Journal: Journal of Thoracic Oncology (2019)
P1.01-110 Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol
Authors: D. Spigel, M. Garassino, B. Besse, A. Sacher, M. Barve, S. Cousin, M. Schenker, D. Rogan, S. Yadavilli, A. Acusta, O. Amit, A. Leighton-Swayze, M. Ballas, A. Hoos, M. Reck
Journal: Journal of Thoracic Oncology (2019)
Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer
Authors: Francesco Fabbri, Samanta Salvi, Sara Bravaccini
Journal: Seminars in Cancer Biology (2019)

Triple negative breast cancer (TNBC) is one of the most biologically aggressive and very often lethal breast disease. It is one of the most puzzling women malignancies, and it currently appears not to be a good candidate to a standardized, unanimously accepted and sufficiently active therapeutic strategy. Fast proliferating and poorly differentiated, it is histopathologically heterogeneous, and even more ambiguous at the molecular level, offering few recurrent actionable targets to the clinicians. It is a formidable and vicious enemy that requires a huge investigational effort to find its vital weak spots. Here, we provide a broad review of "old but gold" biological aspects that taken together may help in finding new TNBC management strategies. A better and updated knowledge of the origins, war-like tactics, refueling mechanisms and escape routes of TNBC, will help in moving the decisive steps towards its final defeat.
P2.04-19 Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC
Authors: P. Gaudreau, M. Negrao, K. Mitchell, E. Corsini, T. Karpinets, Q. Wang, L. Diao, J. Wang, L. Federico, E. Parra, J. Li, C. Behrens, A. Correa, D. Gomez, A. Vaporciyan, A. Weissferdt, H. Tran, E. Roarty, I. Wistuba, A. Reuben, C. Haymaker, C. Bernatchez, T. Cascone, J. Heymach, B. Sepesi, J. Zhang, D. Gibbons
Journal: Journal of Thoracic Oncology (2019)
5‐Aminolevulinic Acid‐Loaded Hyaluronic Acid Dissolving Microneedles for Effective Photodynamic Therapy of Superficial Tumors with Enhanced Long‐Term Stability
Authors: Jinjin Zhu, Liyun Dong, Hongyao Du, Jinzhu Mao, Ying Xie, Hua Wang, Jiajia Lan, Yuchen Lou, Yangxue Fu, Jingjing Wen, Biling Jiang, Yuce Li, Jintao Zhu, Juan Tao
Journal: Advanced Healthcare Materials (2019)

Abstract 5‐Aminolevulinic acid (5‐ALA) is one of the most widely used prodrug in clinical photodynamic therapy of dermatological diseases and cancers; yet, its clinical application is still limited by the shallow skin penetration and unsatisfied stability in any existed formulations. Here, 5‐ALA‐loaded hyaluronic acid dissolving microneedles (5‐ALA@HAMNs) are prepared for photodynamic therapy of superficial tumors. The HAMNs can not only assist the loaded 5‐ALA to effectively penetrate the stratum corneum but also provide 5‐ALA with an acidic and oxygen‐free environment to reduce the dimerization of 5‐ALA molecules via Schiff‐base bonds and formation of inactive pyrazine derivatives, thus maintaining its chemical structure and biological activity. The chemical stability of 5‐ALA in HAMNs is confirmed by UV–vis spectra and mass spectra measurements. The 5‐ALA@HAMNs display remarkable tumor elimination both in vitro and in vivo, even after storage at room temperature for nine months, making it a highly potential device for effective delivery of 5‐ALA in cancer photodynamic therapy.
Altered Transcriptome Uniquely Associated with AML Vs. Normal Hematopoiesis
Authors: Yu Fan, Ying Hu, Cu Nguyen, Chunhua Yan, Rhonda E. Ries, Hamid Bolouri, Jenny L. Smith, Qingrong Chen, E. Anders Kolb, Soheil Meshinchi, Daoud Meerzaman
Journal: Blood (2017)